PureTech Health (PRTC) announced the publication of new research in BMC Pulmonary Medicine that provides a view into the lived experiences of people with idiopathic pulmonary fibrosis. The study identifies critical barriers to treatment, opportunities for improved community engagement, and the need for patient-centered approaches in the development of new therapeutics. Initial findings from this research were presented at the 2023 Pulmonary Fibrosis Foundation Summit, the American Thoracic Society 2024 International Conference, and the CHEST 2024 Annual Meeting.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Optimistic Buy Rating on PureTech Health Driven by Promising LYT-100 Developments and Strategic Growth Plans
- PureTech Health Reports Strong 2024 Financial Results
- PureTech Health confirms discussions with Nordic Capital Epsilon SCA
- PureTech Health plc – American Depositary Shares trading resumes
- PureTech Health plc – American Depositary Shares trading halted, volatility trading pause
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue